THE EFFICIENCY OF THE TYROSINE KINASE INHIBITORS IN THE CHRONIC PHASE OF THE CHRONIC MYELOID LEUKAEMIA
Abstract:
The treatment of the chronic myeloid leukaemia
(CML) was revolutionized when the tyrosine-kinase
inhibitors were discovered, with imatinib 400mg/day po
succeeding to keep under control the disease for many
years. In the case of patients with suboptimal or no
response, the increase in the imatinib dose to 600mg/day
or 800mg/day can still be efficient or other options could
be taken into consideration, such as the use of the second
generation of tyrosine-kinase inhibitors (dasatinib,
nilotinib, etc) or the stem cell transplant.
full text article in English (.EN) |